Updated guidance for palivizumab prophylaxis among infants and young children at increased risk of hospitalization for respiratory syncytial virus infection

Michael T. Brady, Carrie L. Byington, H. Dele Davies, Kathryn M. Edwards, Mary Anne Jackson, Yvonne A. Maldonado, Dennis L Murray, Walter A. Orenstein, Mobeen H. Rathore, Mark H. Sawyer, Gordon E. Schutze, Rodney E. Willoughby, Theoklis E. Zaoutis, Henry H. Bernstein, David W. Kimberlin, Sarah S. Long, H. Cody Meissner, Marc A. Fischer, Bruce G. Gellin, Richard L. Gorman & 33 others Lucia H. Lee, R. Douglas Pratt, Jennifer S. Read, Joan L. Robinson, Marco Aurelio Palazzi Safadi, Jane F. Seward, Jeffrey R. Starke, Geoffrey R. Simon, Tina Q. Tan, Joseph A. Bocchini, W. Robert Morrow, Larry K. Pickering, Geoffrey L. Rosenthal, Dan L. Stewart, Jennifer M. Frantz, Shawn L. Ralston, Allan S. Lieberthal, Brian K. Alverson, Jill E. Baley, Anne M. Gadomski, David W. Johnson, Michael J. Light, Nizar F. Maraqa, Eneida A. Mendonca, Kieran J. Phelan, Joseph J. Zorc, Danette Stanko-Lopp, Sinsi Hernández-Cancio, Mark A. Brown, Ian Nathanson, Elizabeth Rosenblum, Stephen Sayles, Caryn Davidson

Research output: Contribution to journalReview article

228 Citations (Scopus)

Abstract

Palivizumab was licensed in June 1998 by the Food and Drug Administration for the reduction of serious lower respiratory tract infection caused by respiratory syncytial virus (RSV) in children at increased risk of severe disease. Since that time, the American Academy of Pediatrics has updated its guidance for the use of palivizumab 4 times as additional data became available to provide a better understanding of infants and young children at greatest risk of hospitalization attributable to RSV infection. The updated recommendations in this policy statement reflect new information regarding the seasonality of RSV circulation, palivizumab pharmacokinetics, the changing incidence of bronchiolitis hospitalizations, the effect of gestational age and other risk factors on RSV hospitalization rates, the mortality of children hospitalized with RSV infection, the effect of prophylaxis on wheezing, and palivizumab-resistant RSV isolates. This policy statement updates and replaces the recommendations found in the 2012 Red Book.

Original languageEnglish (US)
Pages (from-to)415-420
Number of pages6
JournalPediatrics
Volume134
Issue number2
DOIs
StatePublished - Aug 1 2014

Fingerprint

Respiratory Syncytial Virus Infections
Respiratory Syncytial Viruses
Hospitalization
Child Mortality
Bronchiolitis
Hospitalized Child
Respiratory Sounds
United States Food and Drug Administration
Respiratory Tract Infections
Gestational Age
Pharmacokinetics
Pediatrics
Mortality
Palivizumab
Incidence

Keywords

  • Bronchiolitis
  • Chronic lung disease
  • Congenital heart disease
  • Infants and young children
  • Palivizumab
  • RSV
  • Respiratory syncytial virus

ASJC Scopus subject areas

  • Pediatrics, Perinatology, and Child Health

Cite this

Brady, M. T., Byington, C. L., Davies, H. D., Edwards, K. M., Jackson, M. A., Maldonado, Y. A., ... Davidson, C. (2014). Updated guidance for palivizumab prophylaxis among infants and young children at increased risk of hospitalization for respiratory syncytial virus infection. Pediatrics, 134(2), 415-420. https://doi.org/10.1542/peds.2014-1665

Updated guidance for palivizumab prophylaxis among infants and young children at increased risk of hospitalization for respiratory syncytial virus infection. / Brady, Michael T.; Byington, Carrie L.; Davies, H. Dele; Edwards, Kathryn M.; Jackson, Mary Anne; Maldonado, Yvonne A.; Murray, Dennis L; Orenstein, Walter A.; Rathore, Mobeen H.; Sawyer, Mark H.; Schutze, Gordon E.; Willoughby, Rodney E.; Zaoutis, Theoklis E.; Bernstein, Henry H.; Kimberlin, David W.; Long, Sarah S.; Meissner, H. Cody; Fischer, Marc A.; Gellin, Bruce G.; Gorman, Richard L.; Lee, Lucia H.; Pratt, R. Douglas; Read, Jennifer S.; Robinson, Joan L.; Safadi, Marco Aurelio Palazzi; Seward, Jane F.; Starke, Jeffrey R.; Simon, Geoffrey R.; Tan, Tina Q.; Bocchini, Joseph A.; Morrow, W. Robert; Pickering, Larry K.; Rosenthal, Geoffrey L.; Stewart, Dan L.; Frantz, Jennifer M.; Ralston, Shawn L.; Lieberthal, Allan S.; Alverson, Brian K.; Baley, Jill E.; Gadomski, Anne M.; Johnson, David W.; Light, Michael J.; Maraqa, Nizar F.; Mendonca, Eneida A.; Phelan, Kieran J.; Zorc, Joseph J.; Stanko-Lopp, Danette; Hernández-Cancio, Sinsi; Brown, Mark A.; Nathanson, Ian; Rosenblum, Elizabeth; Sayles, Stephen; Davidson, Caryn.

In: Pediatrics, Vol. 134, No. 2, 01.08.2014, p. 415-420.

Research output: Contribution to journalReview article

Brady, MT, Byington, CL, Davies, HD, Edwards, KM, Jackson, MA, Maldonado, YA, Murray, DL, Orenstein, WA, Rathore, MH, Sawyer, MH, Schutze, GE, Willoughby, RE, Zaoutis, TE, Bernstein, HH, Kimberlin, DW, Long, SS, Meissner, HC, Fischer, MA, Gellin, BG, Gorman, RL, Lee, LH, Pratt, RD, Read, JS, Robinson, JL, Safadi, MAP, Seward, JF, Starke, JR, Simon, GR, Tan, TQ, Bocchini, JA, Morrow, WR, Pickering, LK, Rosenthal, GL, Stewart, DL, Frantz, JM, Ralston, SL, Lieberthal, AS, Alverson, BK, Baley, JE, Gadomski, AM, Johnson, DW, Light, MJ, Maraqa, NF, Mendonca, EA, Phelan, KJ, Zorc, JJ, Stanko-Lopp, D, Hernández-Cancio, S, Brown, MA, Nathanson, I, Rosenblum, E, Sayles, S & Davidson, C 2014, 'Updated guidance for palivizumab prophylaxis among infants and young children at increased risk of hospitalization for respiratory syncytial virus infection', Pediatrics, vol. 134, no. 2, pp. 415-420. https://doi.org/10.1542/peds.2014-1665
Brady, Michael T. ; Byington, Carrie L. ; Davies, H. Dele ; Edwards, Kathryn M. ; Jackson, Mary Anne ; Maldonado, Yvonne A. ; Murray, Dennis L ; Orenstein, Walter A. ; Rathore, Mobeen H. ; Sawyer, Mark H. ; Schutze, Gordon E. ; Willoughby, Rodney E. ; Zaoutis, Theoklis E. ; Bernstein, Henry H. ; Kimberlin, David W. ; Long, Sarah S. ; Meissner, H. Cody ; Fischer, Marc A. ; Gellin, Bruce G. ; Gorman, Richard L. ; Lee, Lucia H. ; Pratt, R. Douglas ; Read, Jennifer S. ; Robinson, Joan L. ; Safadi, Marco Aurelio Palazzi ; Seward, Jane F. ; Starke, Jeffrey R. ; Simon, Geoffrey R. ; Tan, Tina Q. ; Bocchini, Joseph A. ; Morrow, W. Robert ; Pickering, Larry K. ; Rosenthal, Geoffrey L. ; Stewart, Dan L. ; Frantz, Jennifer M. ; Ralston, Shawn L. ; Lieberthal, Allan S. ; Alverson, Brian K. ; Baley, Jill E. ; Gadomski, Anne M. ; Johnson, David W. ; Light, Michael J. ; Maraqa, Nizar F. ; Mendonca, Eneida A. ; Phelan, Kieran J. ; Zorc, Joseph J. ; Stanko-Lopp, Danette ; Hernández-Cancio, Sinsi ; Brown, Mark A. ; Nathanson, Ian ; Rosenblum, Elizabeth ; Sayles, Stephen ; Davidson, Caryn. / Updated guidance for palivizumab prophylaxis among infants and young children at increased risk of hospitalization for respiratory syncytial virus infection. In: Pediatrics. 2014 ; Vol. 134, No. 2. pp. 415-420.
@article{5f783ffde15f48c794f0d32b02298c4e,
title = "Updated guidance for palivizumab prophylaxis among infants and young children at increased risk of hospitalization for respiratory syncytial virus infection",
abstract = "Palivizumab was licensed in June 1998 by the Food and Drug Administration for the reduction of serious lower respiratory tract infection caused by respiratory syncytial virus (RSV) in children at increased risk of severe disease. Since that time, the American Academy of Pediatrics has updated its guidance for the use of palivizumab 4 times as additional data became available to provide a better understanding of infants and young children at greatest risk of hospitalization attributable to RSV infection. The updated recommendations in this policy statement reflect new information regarding the seasonality of RSV circulation, palivizumab pharmacokinetics, the changing incidence of bronchiolitis hospitalizations, the effect of gestational age and other risk factors on RSV hospitalization rates, the mortality of children hospitalized with RSV infection, the effect of prophylaxis on wheezing, and palivizumab-resistant RSV isolates. This policy statement updates and replaces the recommendations found in the 2012 Red Book.",
keywords = "Bronchiolitis, Chronic lung disease, Congenital heart disease, Infants and young children, Palivizumab, RSV, Respiratory syncytial virus",
author = "Brady, {Michael T.} and Byington, {Carrie L.} and Davies, {H. Dele} and Edwards, {Kathryn M.} and Jackson, {Mary Anne} and Maldonado, {Yvonne A.} and Murray, {Dennis L} and Orenstein, {Walter A.} and Rathore, {Mobeen H.} and Sawyer, {Mark H.} and Schutze, {Gordon E.} and Willoughby, {Rodney E.} and Zaoutis, {Theoklis E.} and Bernstein, {Henry H.} and Kimberlin, {David W.} and Long, {Sarah S.} and Meissner, {H. Cody} and Fischer, {Marc A.} and Gellin, {Bruce G.} and Gorman, {Richard L.} and Lee, {Lucia H.} and Pratt, {R. Douglas} and Read, {Jennifer S.} and Robinson, {Joan L.} and Safadi, {Marco Aurelio Palazzi} and Seward, {Jane F.} and Starke, {Jeffrey R.} and Simon, {Geoffrey R.} and Tan, {Tina Q.} and Bocchini, {Joseph A.} and Morrow, {W. Robert} and Pickering, {Larry K.} and Rosenthal, {Geoffrey L.} and Stewart, {Dan L.} and Frantz, {Jennifer M.} and Ralston, {Shawn L.} and Lieberthal, {Allan S.} and Alverson, {Brian K.} and Baley, {Jill E.} and Gadomski, {Anne M.} and Johnson, {David W.} and Light, {Michael J.} and Maraqa, {Nizar F.} and Mendonca, {Eneida A.} and Phelan, {Kieran J.} and Zorc, {Joseph J.} and Danette Stanko-Lopp and Sinsi Hern{\'a}ndez-Cancio and Brown, {Mark A.} and Ian Nathanson and Elizabeth Rosenblum and Stephen Sayles and Caryn Davidson",
year = "2014",
month = "8",
day = "1",
doi = "10.1542/peds.2014-1665",
language = "English (US)",
volume = "134",
pages = "415--420",
journal = "Pediatrics",
issn = "0031-4005",
publisher = "American Academy of Pediatrics",
number = "2",

}

TY - JOUR

T1 - Updated guidance for palivizumab prophylaxis among infants and young children at increased risk of hospitalization for respiratory syncytial virus infection

AU - Brady, Michael T.

AU - Byington, Carrie L.

AU - Davies, H. Dele

AU - Edwards, Kathryn M.

AU - Jackson, Mary Anne

AU - Maldonado, Yvonne A.

AU - Murray, Dennis L

AU - Orenstein, Walter A.

AU - Rathore, Mobeen H.

AU - Sawyer, Mark H.

AU - Schutze, Gordon E.

AU - Willoughby, Rodney E.

AU - Zaoutis, Theoklis E.

AU - Bernstein, Henry H.

AU - Kimberlin, David W.

AU - Long, Sarah S.

AU - Meissner, H. Cody

AU - Fischer, Marc A.

AU - Gellin, Bruce G.

AU - Gorman, Richard L.

AU - Lee, Lucia H.

AU - Pratt, R. Douglas

AU - Read, Jennifer S.

AU - Robinson, Joan L.

AU - Safadi, Marco Aurelio Palazzi

AU - Seward, Jane F.

AU - Starke, Jeffrey R.

AU - Simon, Geoffrey R.

AU - Tan, Tina Q.

AU - Bocchini, Joseph A.

AU - Morrow, W. Robert

AU - Pickering, Larry K.

AU - Rosenthal, Geoffrey L.

AU - Stewart, Dan L.

AU - Frantz, Jennifer M.

AU - Ralston, Shawn L.

AU - Lieberthal, Allan S.

AU - Alverson, Brian K.

AU - Baley, Jill E.

AU - Gadomski, Anne M.

AU - Johnson, David W.

AU - Light, Michael J.

AU - Maraqa, Nizar F.

AU - Mendonca, Eneida A.

AU - Phelan, Kieran J.

AU - Zorc, Joseph J.

AU - Stanko-Lopp, Danette

AU - Hernández-Cancio, Sinsi

AU - Brown, Mark A.

AU - Nathanson, Ian

AU - Rosenblum, Elizabeth

AU - Sayles, Stephen

AU - Davidson, Caryn

PY - 2014/8/1

Y1 - 2014/8/1

N2 - Palivizumab was licensed in June 1998 by the Food and Drug Administration for the reduction of serious lower respiratory tract infection caused by respiratory syncytial virus (RSV) in children at increased risk of severe disease. Since that time, the American Academy of Pediatrics has updated its guidance for the use of palivizumab 4 times as additional data became available to provide a better understanding of infants and young children at greatest risk of hospitalization attributable to RSV infection. The updated recommendations in this policy statement reflect new information regarding the seasonality of RSV circulation, palivizumab pharmacokinetics, the changing incidence of bronchiolitis hospitalizations, the effect of gestational age and other risk factors on RSV hospitalization rates, the mortality of children hospitalized with RSV infection, the effect of prophylaxis on wheezing, and palivizumab-resistant RSV isolates. This policy statement updates and replaces the recommendations found in the 2012 Red Book.

AB - Palivizumab was licensed in June 1998 by the Food and Drug Administration for the reduction of serious lower respiratory tract infection caused by respiratory syncytial virus (RSV) in children at increased risk of severe disease. Since that time, the American Academy of Pediatrics has updated its guidance for the use of palivizumab 4 times as additional data became available to provide a better understanding of infants and young children at greatest risk of hospitalization attributable to RSV infection. The updated recommendations in this policy statement reflect new information regarding the seasonality of RSV circulation, palivizumab pharmacokinetics, the changing incidence of bronchiolitis hospitalizations, the effect of gestational age and other risk factors on RSV hospitalization rates, the mortality of children hospitalized with RSV infection, the effect of prophylaxis on wheezing, and palivizumab-resistant RSV isolates. This policy statement updates and replaces the recommendations found in the 2012 Red Book.

KW - Bronchiolitis

KW - Chronic lung disease

KW - Congenital heart disease

KW - Infants and young children

KW - Palivizumab

KW - RSV

KW - Respiratory syncytial virus

UR - http://www.scopus.com/inward/record.url?scp=84905278885&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84905278885&partnerID=8YFLogxK

U2 - 10.1542/peds.2014-1665

DO - 10.1542/peds.2014-1665

M3 - Review article

VL - 134

SP - 415

EP - 420

JO - Pediatrics

JF - Pediatrics

SN - 0031-4005

IS - 2

ER -